Sexual Dimorphism: The Aging Kidney, Involvement of Nitric Oxide Deficiency, and Angiotensin II Overactivity
Author:
Open Access
- 7 September 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 67 (12) , 1365-1372
Abstract
Females develop less age-dependent loss of renal function, which may be in part due to cardiorenal protective effects of estrogens. The impact of androgen level on cardiovascular–renal health is controversial. Estrogen acts through multiple mechanisms, sometimes beneficial, sometimes damaging, which makes it difficult to predict the effect of hormone replacement therapy (HRT) in an aging population. Nitric oxide (NO) deficiency occurs in aging and contributes to age-dependent cardiovascular risk and kidney damage. The increased oxidative stress of aging has effects at multiple sites in the NO biosynthetic pathway to lower NO production/action. Loss of NO together with activated angiotensin promotes some of the decrements in cardiovascular–renal function seen with age, which may be related to actions of the sex steroids.Keywords
This publication has 107 references indexed in Scilit:
- Sex differences in primary hypertensionBiology of Sex Differences, 2012
- Twelve weeks of treadmill exercise does not alter age‐dependent chronic kidney disease in the Fisher 344 male ratThe Journal of Physiology, 2011
- Evidence That the G Protein–Coupled Membrane Receptor GPR30 Contributes to the Cardiovascular Actions of EstrogenGender Medicine, 2011
- Intrarenal angiotensin II and its contribution to the genesis of chronic hypertensionCurrent Opinion in Pharmacology, 2011
- Disruption of the Ang II type 1 receptor promotes longevity in miceJournal of Clinical Investigation, 2009
- Splice variants of neuronal nitric oxide synthase are present in the rat kidneyNephrology Dialysis Transplantation, 2008
- Lewis K. Dahl Memorial LectureHypertension, 2008
- Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up studyKidney International, 2007
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998